Neurocrine Reports Positive One-Year Data for CAH Treatment

Neurocrine reports positive one-year data for CAH treatment

Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday reported new positive data from the Phase 3 CAHtalyst Adult study of Crenessity in adults with classic congenital adrenal hyperplasia (CAH).

Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting

Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year…

Neurocrine Shares New One-year Data Of Crenessity Trial For CAH - Data Intelligence

Neurocrine’s Crenessity is an oral corticotropin-releasing factor type 1 receptor antagonist. Credit: Piotr Swat/Shutterstock. Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity (crinecerfont) for classic congenital adrenal hyperplasia (CAH). The data revealed that the therapy enabled subjects to achieve more physiological glucocorticoid doses while adrenocorticotropic hormone, 17-hydrox…

Novel Cushing's Syndrome Drug Improves Hypertension, Hyperglycemia

(MedPage Today) — SAN FRANCISCO — The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood pressure, fasting glucose, and weight for patients with adrenal hypercortisolism, a pair of phase III… Source link : https://www.medpagetoday.com/meetingcoverage/endo/116508 Author : Publish date : 2025-07-15 19:03:00 Copyright for syndicated content belongs to the linked Source. The post Novel Cushing’s Syn…

Neurocrine shares new one-year data from trial of Crenessity for CAH

Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity for classic CAH.The post Neurocrine shares new one-year data from trial of Crenessity for CAH appeared first on Clinical Trials Arena.